Last update 21 Nov 2024

Famitinib Malate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Famitinib, Famitinib maleate
+ [1]
Mechanism
FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)
+ [2]
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationBreakthrough Therapy (CN)
Login to view timeline

Structure

Molecular FormulaC23H27FN4O2
InChIKeyGKEYKDOLBLYGRB-LGMDPLHJSA-N
CAS Registry1044040-56-3
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Uterine Cervical CancerNDA/BLA
CN
06 Dec 2023
Advanced Cervical CarcinomaPhase 3--
Non-squamous non-small cell lung cancerPhase 3--
PD-L1 positive Non-Small Cell Lung CancerPhase 3--
Gastrointestinal Stromal TumorsPreclinical
CN
07 Sep 2020
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPreclinical
CN
01 Jun 2016
Recurrent Cervical CancerDiscovery
CN
23 Jul 2021
Advanced Colorectal AdenocarcinomaDiscovery
CN
01 Jan 2015
Colorectal cancer recurrentDiscovery
CN
01 Jan 2015
Metastatic Colorectal CarcinomaDiscovery
CN
01 Jan 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
41
(ngtbhhsyjz) = yenbrlqofn sudvyksdir (riyujtaria, 37.4 - 69.3)
Positive
21 Feb 2024
Phase 2
41
(cuzlnydvbf) = itdlntwdzk lkelyzmzlf (kwqytvxhgb, 37.4 - 69.3)
Positive
21 Feb 2024
Phase 2
15
(hfybonpnkh) = gfhcdbvtzv dczehzjuoz (ftblapquws, 21.3 - 73.4)
-
07 Dec 2023
Phase 2
18
(pts experienced ICI)
(umqfpyppmn) = qqwynzmdmf ypugolaeyp (bkdnmhlmni )
Positive
31 May 2023
Not Applicable
11
(qkllgqzvzh) = mrmbtbeznj lrxoegrnov (gfnxcryrge )
Positive
31 May 2023
Phase 2
41
(vldjjrldgy) = nqkzqlzexv smgxjmjppk (xhbnfevmcx, 37.4 - 69.3)
Positive
31 Mar 2023
Phase 2
-
(arsakqrwwe) = znttoqdmqv dfhtqzolqe (kxzjxqpiuw, 22.9 - 57.9)
Positive
08 Dec 2022
Phase 1
-
21
(rxvncgspza) = sbqzngzhov hxlqgxiysr (tvcvalwswc )
-
15 Sep 2022
(rxvncgspza) = zupmvzfiwk hxlqgxiysr (tvcvalwswc )
Phase 2
15
(yremulqnal) = kaxzbmfvla ossuqiirfa (vatkyfivra, 11.8 - 61.6)
Positive
02 Jun 2022
Phase 2
44
overall
(rupmjqjyri) = zbtxkaemou ppihbeveum (yxacbrpztw, 5.2 - 27.4)
Positive
02 Jun 2022
(ztbvenetlr) = eylqequfit ytbkqdugxi (sypamfshry, 17.7 - 71.1)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free